Financial Tear Sheet

Corporate Profile

Laboratory Corporation of America® Holdings (NYSE: LH), an S&P 500 company, is the world’s leading healthcare diagnostics company, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster and develops technology-enabled solutions to change the way care is provided. With net revenue in excess of $8.5 billion in 2015, LabCorp’s 50,000 employees serve clients in 60 countries. To learn more about LabCorp, visit www.labcorp.com,and to learn more about Covance Drug Development, visit www.covance.com.

More Information

Primary IR Contact
Scott Frommer
Vice President, Investor Relations
Laboratory Corporation of America Holdings
Phone: 336-436-5076
Fax: 336-436-1569
E-mail: investor@labcorp.com

Stock Performance
LH (Common)
ExchangeNYSE (US Dollar)
Price$155.07
Change (%) Stock is Up 1.18 (0.77%)
Volume510,718
52 Week Low$119.51
Market Cap$15,786,126,000
Rolling EPS7.14
PE Ratio21.7185
Shares Outstanding101,800,000
Data as of 09/22/17 4:02 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.
Stock chart for: LH.  Currently trading at $155.07 with a 52 week high of $164.22 and a 52 week low of $119.51.
Recent News & Events
09/14/17 - 3:05 p.m.
LabCorp Presents Nine Studies, Including Novel Research on Improving Genetic Counseling Quality, at the National Society of Genetic Counselors Annual Conference
09/11/17 - 4:15 p.m.
LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest
09/07/17 - 6:30 p.m.
LabCorp Named Among “The World’s Most Innovative Companies” in Forbes’ 2017 Ranking
There are currently no events scheduled.
Analyst Estimates / Ratings
Mean Recommendation: 2.2

Buy
SellStrong Buy
EPS Trend
  Current30 Days Ago90 Days Ago
QTRSep 172.442.442.44
QTRDec 172.402.382.36
QTRMar 182.402.372.34
QTRJun 182.742.692.65
FYDec 179.539.509.44
FYDec 1810.5210.3910.19
SEC Filings
Filing DateForm
09/15/178-K XBRL SEC Filing Unavailable
09/14/178-K XBRL SEC Filing Unavailable
09/12/178-K XBRL SEC Filing Unavailable
09/08/178-K XBRL SEC Filing Unavailable
Corporate Governance
David P.  KingChairman and Chief Executive Officer
Glenn A. EisenbergExecutive Vice President and Chief Financial Officer
Gary M. HuffChief Executive Officer, LabCorp Diagnostics
John D.  RatliffChief Executive Officer, Covance Drug Development
Lance V. BerberianSenior Vice President and Chief Information Officer
Edward T. DodsonSenior Vice President and Chief Accounting Officer
F. Samuel Eberts IIISenior Vice President, Chief Legal Officer and Secretary
Lisa J. UthgenanntChief Human Resources Officer
Ownership Summary
Shareholders
 HoldersValue ($MM)% O/SShares
Institution95614,984.0495.197,429,436
Mutual Fund1,3317,111.4645.646,653,409
Insider *1858.450.4390,073
*Insider values reflect direct beneficial ownership.
Top Holders
 Shares Held% O/SShare ChangeFiling Date
The Vanguard Group, Inc.10,361,89110.1231,60006/30/17
BlackRock Institutional Trust Company, N.A.5,569,1915.45,90006/30/17
Boston Partners4,590,3724.5210,13806/30/17
State Street Global Advisors (US)4,588,2524.5-51,56106/30/17
Nordea Funds Oy2,696,8512.654,10006/30/17
Glenview Capital Management, LLC2,664,9882.6006/30/17
Fidelity Management & Research Company1,754,1061.7158,09006/30/17
Iridian Asset Management LLC1,600,2781.6-7,92506/30/17
Dimensional Fund Advisors, L.P.1,395,0401.467,41106/30/17
Ariel Investments, LLC1,384,8161.4-11,54106/30/17